Ignite Creation Date:
2025-12-24 @ 7:15 PM
Ignite Modification Date:
2025-12-25 @ 4:52 PM
Study NCT ID:
NCT00715403
Status:
COMPLETED
Last Update Posted:
2014-12-02
First Post:
2008-07-11
Is NOT Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
A Phase I/II Open Label Extension Study of BIBF 1120 Administered Orally Once or Twice Daily to Establish Safety, Pharmacokinetics and Efficacy in Patients With Advanced Solid Tumours and Clinical Benefit From Previous Therapy With BIBF 1120
Sponsor:
Boehringer Ingelheim
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2004-10
Start Date Type:
None
Primary Completion Date:
2009-09
Primary Completion Date Type:
ACTUAL
Completion Date:
None
Completion Date Type:
None
First Submit Date:
2008-07-11
First Submit QC Date:
None
Study First Post Date:
2008-07-15
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2014-11-14
Results First Submit QC Date:
None
Results First Post Date:
2014-12-02
Results First Post Date Type:
ESTIMATED
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2014-11-24
Last Update Post Date:
2014-12-02
Last Update Post Date Type:
ESTIMATED